ABN AMRO Bank N.V. Sells 9,349 Shares of Eli Lilly and Company $LLY

ABN AMRO Bank N.V. decreased its position in shares of Eli Lilly and Company (NYSE:LLY) by 3.8% during the 1st quarter, Holdings Channel.com reports. The firm owned 239,700 shares of the company’s stock after selling 9,349 shares during the quarter. Eli Lilly and Company accounts for 2.4% of ABN AMRO Bank N.V.’s investment portfolio, making the stock its 10th biggest holding. ABN AMRO Bank N.V.’s holdings in Eli Lilly and Company were worth $221,188,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently added to or reduced their stakes in the company. Maryland Capital Advisors Inc. bought a new position in Eli Lilly and Company during the fourth quarter valued at about $25,000. Osbon Capital Management LLC acquired a new stake in Eli Lilly and Company in the 4th quarter valued at about $25,000. Basso Capital Management L.P. bought a new position in shares of Eli Lilly and Company during the 4th quarter valued at about $30,000. Miller Global Investments LLC acquired a new position in shares of Eli Lilly and Company in the 4th quarter worth approximately $33,000. Finally, E Fund Management Hong Kong Co. Ltd. lifted its stake in Eli Lilly and Company by 342.9% during the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock valued at $32,000 after purchasing an additional 24 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The European Medicines Agency’s CHMP recommended approval of Jaypirca (pirtobrutinib) for adults with chronic lymphocytic leukemia across all lines of therapy, which could expand Lilly’s oncology revenue opportunity in the EU. Article Title
• Positive Sentiment: Investors are also focused on Lilly’s obesity franchise, with new details on the Medicare GLP-1 Bridge program that could broaden access to Foundayo (orforglipron) and Zepbound for eligible Medicare Part D patients starting July 1. Article Title
• Positive Sentiment: Management’s expanded access push and continued clinical progress in obesity/diabetes are reinforcing the view that Lilly remains a leader in the weight-loss drug race, supporting bullish sentiment. Article Title
• Neutral Sentiment: Some recent coverage highlights Lilly’s strong pipeline and market leadership, but also notes valuation concerns and a less attractive entry point after the stock’s big run. Article Title
• Neutral Sentiment: News about Lilly launching its cancer drug Tanstrive in India adds another growth angle, but it appears to be a smaller near-term stock driver than the obesity and EU approval updates. Article Title

Eli Lilly and Company Price Performance

LLY opened at $1,206.51 on Monday. The stock has a fifty day moving average of $1,036.28 and a 200-day moving average of $1,021.13. The firm has a market capitalization of $1.14 trillion, a P/E ratio of 42.86, a PEG ratio of 1.32 and a beta of 0.53. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,215.76. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The business had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.Eli Lilly and Company’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities analysts forecast that Eli Lilly and Company will post 35.8 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company’s payout ratio is 24.58%.

Wall Street Analysts Forecast Growth

LLY has been the topic of several recent research reports. Barclays lifted their price target on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an “overweight” rating in a research report on Monday, May 4th. BMO Capital Markets reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research report on Monday, June 15th. Rothschild & Co Redburn increased their price target on Eli Lilly and Company from $880.00 to $900.00 in a research report on Thursday, May 7th. Berenberg Bank lifted their price target on Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the stock a “hold” rating in a research note on Monday, June 22nd. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Eli Lilly and Company in a report on Monday, June 22nd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $1,235.07.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.